Drug General Information
Drug ID
D05SVA
Former ID
DNC007222
Drug Name
5-(piperidin-4-yl)isoxazol-3-ol
Synonyms
5-Piperidin-4-yl-isoxazol-3-ol
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527382]
Structure
Download
2D MOL

3D MOL

Formula
C8H12N2O2
Canonical SMILES
C1CNCCC1C2=CC(=O)NO2
InChI
1S/C8H12N2O2/c11-8-5-7(12-10-8)6-1-3-9-4-2-6/h5-6,9H,1-4H2,(H,10,11)
InChIKey
YYOYGSTYWVHCJR-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Gamma-aminobutyric acid receptor subunit gamma-2 Target Info Inhibitor [527382]
Gamma-aminobutyric acid receptor Target Info Inhibitor [528744]
Gamma-aminobutyric acid receptor subunit beta-2 Target Info Inhibitor [527382]
Gamma-aminobutyric acid receptor subunit alpha-1 Target Info Inhibitor [527382]
KEGG Pathway Neuroactive ligand-receptor interaction
Retrograde endocannabinoid signaling
GABAergic synapse
Morphine addiction
Nicotine addictionhsa04080:Neuroactive ligand-receptor interaction
Serotonergic synapse
Nicotine addiction
Reactome Ligand-gated ion channel transport
GABA A receptor activationR-HSA-975298:Ligand-gated ion channel transport
GABA A receptor activation
WikiPathways Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
Iron uptake and transportWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
Iron uptake and transportWP706:SIDS Susceptibility Pathways
Iron uptake and transport
References
Ref 527382J Med Chem. 2005 Jan 27;48(2):427-39.Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling.
Ref 527382J Med Chem. 2005 Jan 27;48(2):427-39.Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling.
Ref 528744J Med Chem. 2007 Apr 19;50(8):1988-92. Epub 2007 Mar 22.4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology, and structure-activity relationships.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.